|
Stage:
|
Adults and Adolescents (>15yo)
|
Children (<15yo):
|
|
1
|
No disease
|
No disease
|
|
2
|
Angular Chellitis, Recurrent oral ulcerations
|
Angular Chellitis, Linear gingival erythema, extensive warts, Recurrent oral ulcerations, Parotid enlarge
|
|
3
|
Persistent oral candidiasis, Oral hairy leukoplakia, Acute necrotizing ulcerative stomatitis, gingivitis, periodontitis
|
Persistent oral candidiasis (after 8wks), Oral hairy leukoplakia, Acute necrotizing ulcerative gingivitis or periodontitis.
|
|
4
|
Chronic (>1mo) orolabial HSV, Kaposi's sarcoma,
|
Chronic (>1mo) orolabial HSV, Karpo's Sarcoma, Non-Hodgkin's lymphoma
|
|
Infections:
|
- Fungal, Viral, Bacteria
|
|
Neoplams:
|
- Kaposi's Sarcoma, Non-Hodgkin's Lymphoma
|
|
Other:
|
- Aphthous-like Ulcers, Lichenoid or drug reactions, Salivary Gland Disease
|
|
Erythematous Chelitis
|
|
Pseudomembranous
|
|
Angular
|
|
-Herpes Simplex Infection
|
-HPV Lesiosn
|
|
-Cytomegalovirus Infection
|
-Lymphoma
|
|
-Aphthous Ulcers
|
-Necrotizing ulcerative gingivitis/ periodontitis
|
|
-Histoplasmosis
|
-Necrotizing Stomamtitis (NS)
|
|
Topical Therapy:
|
Intralesional:
|
Systemic Therapy:
|
|
Topical Corticosteroids
|
Triamcinolone: 40 mg /ml (0.5 ml-1.0 ml injected bid)
|
Prednisone: 0.5-1.0 mg/kg qd x 7-10d, then taper
|
|
Thalidomide: 200 mg PO qd
|
|
NRTIs:
|
Nucleoside OR Nucleotide Reverse Transcriptase Inhibitors (Nukes)
|
|
NNRTIs:
|
Non-nucleoside Reverse Transcriptase Inhibitors (non-nukes)
|
|
PIs:
|
Protase Inhibitors
|
|
Fusion Inhibitors
|
|
|
Chemokine Receptor Antagonists
|
|
|
Integrase Inhibitors
|
|
|
Nucleoside Analogues Zidovudine (AZT, ZDV) Didanosine (ddI) Zalcitabine (ddC) Stavudine (d4T) Lamivudine (3TC) Abacavir (ABC) Emtricitabine (FTC)
|
Non-nucleoside analogues: Nevirapine (NVP) delavirdine (DLV) Efavirenz (EFV) etravirine (ETV) rilpivirine (RPV)
|
|
Integrase Inhibitors
|
Fusion Inhibitor:
|
Entry Inhibitors:
|
|
raltegravir (RAL)
|
fuzeon (T20)
|
maraviroc (MVC)
|
|
elvitegravir (ELV)
|
||
|
Nucleoside Analogs (like AZT):
|
Analog of thymidine, cytosine or guanine
|
|
Triphosphorylated inside lymphocytes to active compound.
|
|
|
Incorporate into growing HIV viral DNA strand by reverse transcriptase.
|
|
|
Nucleotide Analogs:
|
tenofovir (TDF)
|
|
does NOT need to be tri-phosphorylated only di-phosphorylated to activate compound.
|
|
Agents directly bind to reverse transcriptase to inhibit transcription.
|
|
NNRTIs do not require phosphorylation to be active.
|
|
Protease enzyme cleaves HIV precursor proteins into active proteins that are needed to assemble a new, mature HIV virus.
|
|
PIs bind to protease preventing the cleavage and inhibiting the assembly of new HIV viruses.
|
|
Marviroc (Selzentry)
|
|
CCR5 or CXCR4 receptors on cell surface
|
|
Virus will bind to one of the 2 receptors (some pt virus will bind to either receptors)
|
|
Marviroc blocks viral entry at CCR5
|
|
Dosed 300mg BID= 150mg BID with P450 inhibitors. = 600mg BID with P450 inducers
|
|
Raltegravir (Isentress)
|
|
Dosed = 400mg BID (1tab BID)
|
|
No induction or inhibition on CYP450 enzymes or Pgp
|
|
Metabolized by UGT1A1 (glucuronidation) = Only affected by drugs that inhibit or induce UGTs (ie. rifampin)
|
No comments yet.
Cheatography n. The art of mapping complex subjects into clear, instantly navigable reference guides.